{
    "hands_on_practices": [
        {
            "introduction": "Effective use of biologics begins with correct administration, and for agents like omalizumab, this requires a personalized approach based on patient-specific biomarkers. This exercise simulates the practical task of determining a patient's dose using a validated pharmacokinetic model that links body weight ($W$) and baseline total Immunoglobulin E ($I$) to a target drug exposure. Mastering this calculation bridges the gap between understanding the drug's pharmacodynamic goal—sustained suppression of free IgE—and applying it safely under real-world constraints such as maximum injection volumes and standard dose increments.",
            "id": "5010444",
            "problem": "A patient with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is evaluated for omalizumab therapy. The patient's baseline total Immunoglobulin E ($I$) is $420$ International Units per milliliter (IU/mL), and body weight ($W$) is $82$ kilograms. Omalizumab dosing for CRSwNP follows the same population-pharmacokinetic framework validated in asthma, which targets sustained suppression of free Immunoglobulin E by selecting a monthly dose proportional to baseline $I$ and $W$, using a clinically established proportionality constant $k$ for the four-week total dose.\n\nAssume the following well-tested facts and implementation constraints used in the regulatory dosing algorithm:\n- The four-week total dose is given by $D_{4w} = k \\, W \\, I$, with $k = 0.016$ milligrams per (IU/mL$\\cdot$kg).\n- The injection interval $\\tau$ is chosen from $\\{2, 4\\}$ weeks such that the per-injection dose $D_{\\text{inj}}$ does not exceed $300$ milligrams.\n- The per-injection dose is delivered in integer multiples of $75$ milligrams. To avoid undertreatment relative to the pharmacodynamic target, if $D_{\\text{inj}}$ falls between two adjacent $75$ milligram increments, round $D_{\\text{inj}}$ up to the next higher increment.\n\nUsing these principles and constraints, determine the per-injection omalizumab dose and the dosing interval for this patient. Express the dose in milligrams and the interval in weeks. Clearly explain how you map from $(I, W)$ to $(D_{\\text{inj}}, \\tau)$ under the above rules. No additional clinical shortcuts or tables are permitted; derive your answer from the stated base and constraints.\n\nYour final numeric answer must contain two entries: the per-injection dose (in milligrams) and the interval (in weeks). Do not include units inside the final answer. If any rounding to allowed dose increments is required, apply the increment rule stated above.",
            "solution": "The problem requires the determination of the per-injection dose, $D_{\\text{inj}}$, and the dosing interval, $\\tau$, for omalizumab therapy in a specific patient. The solution must be derived strictly from the provided principles and constraints.\n\n### Step 1: Problem Validation\n\nFirst, I will extract the givens and validate the problem statement.\n\n**Givens:**\n*   Patient's baseline total Immunoglobulin E ($I$): $420$ IU/mL\n*   Patient's body weight ($W$): $82$ kg\n*   Four-week total dose formula: $D_{4w} = k \\, W \\, I$\n*   Proportionality constant ($k$): $0.016$ mg/(IU/mL$\\cdot$kg)\n*   Set of possible injection intervals: $\\tau \\in \\{2, 4\\}$ weeks\n*   Maximum per-injection dose constraint: $D_{\\text{inj}} \\le 300$ mg\n*   Dose increment constraint: $D_{\\text{inj}}$ must be an integer multiple of $75$ mg.\n*   Rounding rule: If the calculated per-injection dose is not an exact multiple of $75$ mg, it must be rounded up to the next higher increment.\n\n**Validation:**\n1.  **Scientific Grounding:** The problem describes a simplified but fundamentally correct pharmacokinetic dosing algorithm for a monoclonal antibody, omalizumab. Dosing based on body weight and a biomarker (total IgE) is a standard practice in biologics therapy. The numerical values for the constant, dose increments, and maximums are consistent with established clinical guidelines for this drug in its approved indications. The problem is scientifically grounded.\n2.  **Well-Posedness:** The problem provides all necessary data ($I$, $W$, $k$) and a complete set of deterministic rules to calculate the desired outputs ($D_{\\text{inj}}$, $\\tau$). The constraints are clear, and there are no contradictions, leading to a unique and meaningful solution.\n3.  **Objectivity:** The problem is stated in precise, quantitative, and unbiased language.\n\n**Verdict:** The problem is valid as it is scientifically grounded, well-posed, and objective. I will proceed with the solution.\n\n### Step 2: Solution Derivation\n\nThe process to determine the dose and interval involves a sequential application of the given rules.\n\n**1. Calculate the Theoretical Four-Week Total Dose ($D_{4w}$)**\n\nThe four-week total dose is calculated using the provided formula:\n$$D_{4w} = k \\, W \\, I$$\nSubstituting the given values:\n*   $k = 0.016 \\, \\text{mg/(IU/mL}\\cdot\\text{kg)}$\n*   $W = 82 \\, \\text{kg}$\n*   $I = 420 \\, \\text{IU/mL}$\n\n$$D_{4w} = (0.016) \\times (82) \\times (420) \\, \\text{mg}$$\n$$D_{4w} = (1.312) \\times (420) \\, \\text{mg}$$\n$$D_{4w} = 551.04 \\, \\text{mg}$$\nThis is the total dose required over a $4$-week period to achieve the target pharmacodynamic effect.\n\n**2. Determine the Dosing Interval ($\\tau$)**\n\nThe dosing interval $\\tau$ must be chosen from the set $\\{2, 4\\}$ weeks. The choice is governed by the constraint that the final per-injection dose, $D_{\\text{inj}}$, cannot exceed $300$ mg. We must evaluate the two possible intervals.\n\n*   **Case 1: Assume a $4$-week interval ($\\tau = 4$ weeks).**\n    If the dose is administered every $4$ weeks, the entire $4$-week dose is given in a single injection. The theoretical per-injection dose would be:\n    $$D_{\\text{inj, theoretical}} = D_{4w} = 551.04 \\, \\text{mg}$$\n    This theoretical dose of $551.04$ mg violates the constraint $D_{\\text{inj}} \\le 300$ mg. Therefore, an interval of $4$ weeks is not permissible for this patient.\n\n*   **Case 2: Assume a $2$-week interval ($\\tau = 2$ weeks).**\n    If the dose is administered every $2$ weeks, the total $4$-week dose is split into two equal injections. The theoretical per-injection dose would be:\n    $$D_{\\text{inj, theoretical}} = \\frac{D_{4w}}{2} = \\frac{551.04}{2} \\, \\text{mg} = 275.52 \\, \\text{mg}$$\n    This dose of $275.52$ mg does not violate the maximum dose constraint ($275.52 \\le 300$). Therefore, the only valid dosing interval is $\\tau = 2$ weeks.\n\n**3. Calculate the Final Per-Injection Dose ($D_{\\text{inj}}$)**\n\nThe final per-injection dose must be an integer multiple of $75$ mg. According to the rounding rule, if the theoretical dose is not an exact multiple, it must be rounded *up* to the next higher increment.\n\nOur theoretical per-injection dose is $275.52$ mg. We find the multiples of $75$ mg:\n*   $1 \\times 75 = 75$\n*   $2 \\times 75 = 150$\n*   $3 \\times 75 = 225$\n*   $4 \\times 75 = 300$\n\nThe theoretical dose $275.52$ mg falls between $225$ mg and $300$ mg. Applying the rule to round up to the next higher increment, we select $300$ mg.\n$$D_{\\text{inj}} = 300 \\, \\text{mg}$$\n\nThis final dose $D_{\\text{inj}} = 300$ mg also satisfies the maximum dose constraint ($300 \\le 300$).\n\n**Conclusion**\nThe analysis determines that the patient requires a per-injection dose of $300$ mg administered every $2$ weeks.\n\nFinal Answer Summary:\n*   Per-injection dose, $D_{\\text{inj}} = 300$ mg.\n*   Dosing interval, $\\tau = 2$ weeks.",
            "answer": "$$\\boxed{\\begin{pmatrix} 300  2 \\end{pmatrix}}$$"
        },
        {
            "introduction": "After initiating a biologic therapy, the critical next step is to objectively measure its impact on the patient. This practice focuses on quantifying treatment response using the Nasal Polyp Score (NPS), a standard endoscopic measure in CRSwNP. You will go beyond simply calculating the change in score to interpret its clinical relevance by comparing it to the Minimally Clinically Important Difference (MCID), a vital concept in evidence-based medicine that helps distinguish a meaningful patient benefit from a statistically detectable but clinically trivial effect.",
            "id": "5010473",
            "problem": "A patient with chronic rhinosinusitis with nasal polyps (CRSwNP) is treated with a biologic therapy targeting type 2 inflammation. Endoscopic assessment uses the Nasal Polyp Score (NPS), defined as the sum of polyp size grades across both nasal cavities, each graded on an integer scale from $0$ (no polyp) to $4$ (complete obstruction), yielding a total score in the range $0$ to $8$. Assume the following data and definitions for quantitative evaluation at week $24$:\n\n- Baseline total NPS is $x_{\\text{baseline}} = 6$.\n- Post-treatment total NPS at week $24$ is $x_{\\text{post}} = 3$.\n- Define the raw absolute change (signed) as $\\Delta = x_{\\text{post}} - x_{\\text{baseline}}$.\n- Define the relative change (signed) as $r = \\dfrac{x_{\\text{post}} - x_{\\text{baseline}}}{x_{\\text{baseline}}}$.\n- For clinical interpretability, adopt a minimally clinically important difference (MCID) threshold for NPS of $\\Delta_{\\text{MCID}} = 1.0$ (points) at week $24$, and define the clinical meaningfulness indicator as $I = \\mathbb{I}\\!\\left(|\\Delta| \\ge \\Delta_{\\text{MCID}}\\right)$, where $\\mathbb{I}(\\cdot)$ is the indicator function that equals $1$ if the condition is true and $0$ otherwise.\n\nUsing only these definitions and the provided data, compute $\\Delta$, $r$, and $I$. Report your final answer as a row matrix $\\begin{pmatrix}\\Delta  r  I\\end{pmatrix}$. Express the relative change $r$ as a decimal or an exact fraction. No rounding is required, and no units are needed for the final values.",
            "solution": "The problem is deemed valid as it is scientifically grounded in the clinical assessment practices of otorhinolaryngology, well-posed with all necessary definitions and data, and objective in its formulation. We can proceed with a direct computation based on the provided definitions.\n\nThe given data are:\n- Baseline total Nasal Polyp Score (NPS): $x_{\\text{baseline}} = 6$\n- Post-treatment total NPS at week $24$: $x_{\\text{post}} = 3$\n- Minimally Clinically Important Difference (MCID) threshold: $\\Delta_{\\text{MCID}} = 1.0$\n\nThe quantities to be computed are $\\Delta$, $r$, and $I$, defined as follows:\n- Raw absolute change (signed): $\\Delta = x_{\\text{post}} - x_{\\text{baseline}}$\n- Relative change (signed): $r = \\dfrac{x_{\\text{post}} - x_{\\text{baseline}}}{x_{\\text{baseline}}}$\n- Clinical meaningfulness indicator: $I = \\mathbb{I}\\!\\left(|\\Delta| \\ge \\Delta_{\\text{MCID}}\\right)$\n\nFirst, we compute the raw absolute change, $\\Delta$, by substituting the given values of $x_{\\text{post}}$ and $x_{\\text{baseline}}$ into its definition:\n$$\n\\Delta = x_{\\text{post}} - x_{\\text{baseline}} = 3 - 6 = -3\n$$\nThe value of $\\Delta$ is $-3$. The negative sign indicates a reduction in the Nasal Polyp Score, which corresponds to a clinical improvement.\n\nNext, we compute the relative change, $r$. We can use the previously calculated value of $\\Delta$:\n$$\nr = \\dfrac{\\Delta}{x_{\\text{baseline}}} = \\dfrac{-3}{6}\n$$\nSimplifying the fraction gives:\n$$\nr = -\\dfrac{1}{2}\n$$\nAs a decimal, this is $r = -0.5$. This represents a $50\\%$ reduction in the NPS relative to the baseline score.\n\nFinally, we compute the clinical meaningfulness indicator, $I$. The definition is $I = \\mathbb{I}\\!\\left(|\\Delta| \\ge \\Delta_{\\text{MCID}}\\right)$. We must first evaluate the condition inside the indicator function, which is $|\\Delta| \\ge \\Delta_{\\text{MCID}}$.\n\nWe need the absolute value of $\\Delta$:\n$$\n|\\Delta| = |-3| = 3\n$$\nNow we compare this to the MCID threshold, $\\Delta_{\\text{MCID}} = 1.0$:\n$$\n3 \\ge 1.0\n$$\nThis inequality is true. Since the condition is true, the indicator function $\\mathbb{I}(\\cdot)$ evaluates to $1$:\n$$\nI = 1\n$$\nThis indicates that the observed change in the NPS is clinically meaningful.\n\nWe are asked to report the final answer as a row matrix $\\begin{pmatrix}\\Delta  r  I\\end{pmatrix}$. Substituting the computed values:\n$$\n\\begin{pmatrix}-3  -0.5  1\\end{pmatrix}\n$$",
            "answer": "$$\n\\boxed{\\begin{pmatrix}-3  -0.5  1\\end{pmatrix}}\n$$"
        },
        {
            "introduction": "While assessing short-term outcomes is essential , managing a chronic disease like CRSwNP requires a long-term strategic perspective that balances efficacy, safety, and cost. This advanced practice introduces health economic modeling via a discrete-time Markov chain, a powerful technique to simulate a cohort's journey through various health states over many years. By building this model, you will learn how to synthesize data on treatment efficacy (transition probabilities), costs, and quality of life (utilities) to compare the long-term value of different strategies, providing a foundation for cost-effectiveness analysis and health policy decisions.",
            "id": "5010450",
            "problem": "Construct a discrete-time Markov chain to evaluate long-term biologic strategies in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a chronic inflammatory disease characterized by nasal polyps and sinus symptoms. Biologic therapy is considered for patients with uncontrolled disease on standard treatments. The Markov model must use the following mutually exclusive states per cycle: Controlled (C), Uncontrolled (U), Surgery (S), Oral Corticosteroid Burst (B), Adverse Event (A). Oral Corticosteroid (OCS) is defined as short, systemic corticosteroid courses for disease exacerbations. Adverse Event (AE) represents clinically important treatment side effects. Standard of Care (SOC) refers to non-biologic conventional management. The Markov chain is parameterized by a monthly cycle length.\n\nFundamental base to use:\n- The Markov property: future state depends only on the current state, not the past. If $p_t$ is the row vector of state probabilities at cycle $t$, and $P$ is the $5 \\times 5$ transition matrix, then $p_{t+1} = p_t P$ and $\\sum_{i=1}^{5} p_t(i) = 1$ for all $t$.\n- Expected value linearity for costs and utilities: the expected cost in a cycle is the dot product of the state distribution and the state cost vector, and similarly for utilities.\n- Time preference via exponential discounting: for annual discount rate $r$, a payoff at month $t$ is discounted by $(1+r)^{-t/12}$.\n\nModel specifications:\n- State order is fixed as $[C,U,S,B,A]$.\n- Cycle length is $1$ month, and the time horizon is $T$ months (specified per test case).\n- Two transition matrices are defined: one for Standard of Care ($P_{\\text{SOC}}$) and one for Biologic strategy ($P_{\\text{BIO}}$). These are monthly transition probabilities, row-stochastic and scientifically plausible.\n\nThe Standard of Care transition matrix is:\n$$\nP_{\\text{SOC}} =\n\\begin{bmatrix}\n0.75  0.15  0.03  0.05  0.02 \\\\\n0.30  0.45  0.10  0.10  0.05 \\\\\n0.55  0.25  0.05  0.10  0.05 \\\\\n0.40  0.40  0.05  0.10  0.05 \\\\\n0.35  0.45  0.04  0.06  0.10 \\\\\n\\end{bmatrix}.\n$$\n\nThe Biologic transition matrix is:\n$$\nP_{\\text{BIO}} =\n\\begin{bmatrix}\n0.85  0.10  0.01  0.02  0.02 \\\\\n0.50  0.35  0.05  0.06  0.04 \\\\\n0.65  0.25  0.02  0.05  0.03 \\\\\n0.55  0.35  0.03  0.04  0.03 \\\\\n0.40  0.45  0.03  0.04  0.08 \\\\\n\\end{bmatrix}.\n$$\n\nPer-cycle state costs (in United States Dollar (USD)) under Standard of Care:\n- $c_C = 150$,\n- $c_U = 300$,\n- $c_S = 5000$,\n- $c_B = 200$,\n- $c_A = 400$ (modifiable in test cases).\n\nBiologic monthly acquisition cost (in USD) added when biologic is active in a cycle:\n- $c_{\\text{bio}} = 2000$.\n\nPer-cycle health state utilities (unitless quality weights):\n- $u_C = 0.90$,\n- $u_U = 0.65$,\n- $u_S = 0.50$,\n- $u_B = 0.60$,\n- $u_A = 0.55$.\n\nInitial state distribution at baseline is:\n$$\np_0 = [0,1,0,0,0],\n$$\nmeaning all patients start Uncontrolled.\n\nPer-cycle expected cost at month $t$ with strategy indicator $\\delta_t \\in \\{0,1\\}$ (where $\\delta_t=1$ if biologic is active in cycle $t$, else $\\delta_t=0$) is computed as:\n$$\n\\text{Cost}_t = \\left(p_t \\cdot c\\right) + \\delta_t \\cdot c_{\\text{bio}},\n$$\nwhere $c = [c_C, c_U, c_S, c_B, c_A]$ and $c_{\\text{bio}}$ is added once per patient per cycle (i.e., applied to the entire cohort expectation). The discounted expected cost is:\n$$\n\\text{DCost}_t = \\text{Cost}_t \\cdot (1+r_c)^{-t/12},\n$$\nwhere $r_c$ is the annual discount rate for costs.\n\nPer-cycle expected Quality-Adjusted Life Years (QALYs) are computed as:\n$$\n\\text{QALY}_t = \\left(p_t \\cdot u\\right) \\cdot \\Delta,\n$$\nwith $u = [u_C, u_U, u_S, u_B, u_A]$ and $\\Delta = \\frac{1}{12}$ years per monthly cycle. The discounted expected QALYs are:\n$$\n\\text{DQALY}_t = \\text{QALY}_t \\cdot (1+r_q)^{-t/12},\n$$\nwhere $r_q$ is the annual discount rate for QALYs.\n\nTotal discounted costs and QALYs over $T$ months are:\n$$\n\\text{TotalCost} = \\sum_{t=1}^{T} \\text{DCost}_t, \\quad\n\\text{TotalQALY} = \\sum_{t=1}^{T} \\text{DQALY}_t.\n$$\n\nDefine the Net Monetary Benefit (NMB) at willingness-to-pay threshold $\\lambda$ (in USD per QALY) as:\n$$\n\\text{NMB} = \\lambda \\cdot \\text{TotalQALY} - \\text{TotalCost}.\n$$\n\nStrategies to be evaluated:\n- Strategy $\\mathcal{S}_1$ (Continuous Biologic): $\\delta_t = 1$ for all $t \\in \\{1,\\dots,T\\}$, using $P_{\\text{BIO}}$ each cycle.\n- Strategy $\\mathcal{S}_2$ (Standard of Care): $\\delta_t = 0$ for all $t \\in \\{1,\\dots,T\\}$, using $P_{\\text{SOC}}$ each cycle.\n- Strategy $\\mathcal{S}_3$ (Adaptive Stop): $\\delta_t = 1$ for $t \\in \\{1,\\dots,12\\}$; for $t \\ge 13$, compute $p_{12}$ and if $p_{12}(C) \\ge \\theta$ then set $\\delta_t = 0$ for all remaining cycles; otherwise, continue with $\\delta_t = 1$. Matrix selection follows $\\delta_t$ at each cycle.\n\nTest suite (each test case defines $T$, $r_c$, $r_q$, strategy, threshold $\\theta$ if applicable, and $c_A$ override):\n- Test Case $1$: $T=60$, $r_c=0.03$, $r_q=0.03$, strategy $\\mathcal{S}_1$, $\\theta$ not used, $c_A=400$.\n- Test Case $2$: $T=60$, $r_c=0.03$, $r_q=0.03$, strategy $\\mathcal{S}_2$, $\\theta$ not used, $c_A=400$.\n- Test Case $3$: $T=60$, $r_c=0.03$, $r_q=0.03$, strategy $\\mathcal{S}_3$, $\\theta=0.60$, $c_A=400$.\n- Test Case $4$: $T=60$, $r_c=0.00$, $r_q=0.00$, strategy $\\mathcal{S}_1$, $\\theta$ not used, $c_A=800$.\n\nAdditional constants common to all tests:\n- Willingness-to-pay threshold $\\lambda = 100000$ USD/QALY.\n\nYour task:\n- Implement the above Markov chain model.\n- For each test case, compute the triplet $[\\text{TotalCost}, \\text{TotalQALY}, \\text{NMB}]$.\n- Express $\\text{TotalCost}$ in USD, rounded to two decimals; $\\text{TotalQALY}$ in years, rounded to four decimals; and $\\text{NMB}$ in USD, rounded to two decimals.\n\nFinal output format:\n- Your program should produce a single line of output containing the results as a comma-separated list enclosed in square brackets, where each element is the three-element list for a test case in the same order as specified above (e.g., $[[c_1,q_1,n_1],[c_2,q_2,n_2],\\dots]$).",
            "solution": "The posed problem is a well-defined application of a discrete-time Markov chain for health economic evaluation, a standard methodology in medical decision-making and health technology assessment. It is scientifically grounded, mathematically consistent, and all parameters required for a unique solution are provided. The problem is therefore deemed valid.\n\nThe core of the solution is to simulate a cohort of patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) over a specified time horizon, tracking the evolution of their disease states and the associated costs and health outcomes under different treatment strategies. The model operates in discrete time steps, or cycles, each representing $1$ month.\n\nThe model is defined by $5$ mutually exclusive health states: Controlled (C), Uncontrolled (U), Surgery (S), Oral Corticosteroid Burst (B), and Adverse Event (A). The state of the cohort at any time $t$ is described by a probability vector $p_t = [p_t(C), p_t(U), p_t(S), p_t(B), p_t(A)]$, where each component represents the proportion of the cohort in the corresponding state, and $\\sum_{i} p_t(i) = 1$. The problem specifies an initial state where the entire cohort begins in the Uncontrolled state, so the initial state vector at time $t=0$ is $p_0 = [0, 1, 0, 0, 0]$.\n\nThe evolution of the system adheres to the Markov property, where the state distribution at the next cycle, $p_{t+1}$, depends only on the current distribution, $p_t$, and a transition probability matrix, $P$. The relationship is given by the matrix multiplication $p_{t+1} = p_t P$. The problem provides two distinct transition matrices: $P_{\\text{SOC}}$ for the Standard of Care strategy and $P_{\\text{BIO}}$ for the Biologic therapy strategy.\n\nThe simulation proceeds iteratively for a total of $T$ cycles (months). For each cycle $t$ from $1$ to $T$, we perform the following steps:\n$1$. The state distribution at the start of cycle $t$ is $p_{t-1}$.\n$2$. The expected cost for cycle $t$ is calculated based on the state distribution $p_{t-1}$. This cost is the sum of the expected state-dependent costs and any treatment-specific costs. The expected state cost is the dot product of the state distribution vector $p_{t-1}$ and the state cost vector $c = [c_C, c_U, c_S, c_B, c_A]$. If a biologic is used in cycle $t$ (indicated by $\\delta_t = 1$), the fixed biologic cost $c_{\\text{bio}}$ is added. The formula is:\n$$\n\\text{Cost}_t = (p_{t-1} \\cdot c) + \\delta_t \\cdot c_{\\text{bio}}\n$$\n$3$. The expected health utility for cycle $t$ is similarly calculated as the dot product of $p_{t-1}$ and the health state utility vector $u = [u_C, u_U, u_S, u_B, u_A]$. This utility is converted to Quality-Adjusted Life Years (QALYs) by multiplying by the cycle length in years, $\\Delta = \\frac{1}{12}$:\n$$\n\\text{QALY}_t = (p_{t-1} \\cdot u) \\cdot \\Delta\n$$\n$4$. Future costs and QALYs are valued less than present ones, a concept captured by discounting. The costs and QALYs for cycle $t$ are discounted back to present value using the annual discount rates for costs, $r_c$, and QALYs, $r_q$. The discounted values are:\n$$\n\\text{DCost}_t = \\text{Cost}_t \\cdot (1+r_c)^{-t/12} \\quad \\text{and} \\quad \\text{DQALY}_t = \\text{QALY}_t \\cdot (1+r_q)^{-t/12}\n$$\nThese discounted values are accumulated over the time horizon $T$ to find the total discounted cost and QALYs for the strategy.\n$$\n\\text{TotalCost} = \\sum_{t=1}^{T} \\text{DCost}_t, \\quad \\text{TotalQALY} = \\sum_{t=1}^{T} \\text{DQALY}_t\n$$\n$5$. After calculating the payoffs for cycle $t$, the state distribution is updated for the start of the next cycle, $t+1$, using the appropriate transition matrix $P_t$, which depends on the active strategy: $p_t = p_{t-1} P_t$.\n\nThe three strategies are implemented as follows:\n- **Strategy $\\mathcal{S}_1$ (Continuous Biologic):** For all cycles $t \\in \\{1,\\dots,T\\}$, the biologic is active ($\\delta_t=1$), so the transition matrix is $P_{\\text{BIO}}$ and the cost $c_{\\text{bio}}$ is added.\n- **Strategy $\\mathcal{S}_2$ (Standard of Care):** For all cycles $t \\in \\{1,\\dots,T\\}$, the biologic is inactive ($\\delta_t=0$), the transition matrix is $P_{\\text{SOC}}$, and no biologic cost is added.\n- **Strategy $\\mathcal{S}_3$ (Adaptive Stop):** This is a dynamic strategy. For the first $12$ cycles, it follows the biologic strategy ($\\delta_t=1, P_t = P_{\\text{BIO}}$). At the end of cycle $12$, the state distribution $p_{12}$ is evaluated. If the proportion of patients in the 'Controlled' state, $p_{12}(C)$, meets or exceeds a threshold $\\theta$, the strategy switches to Standard of Care for all subsequent cycles ($t \\ge 13$, $\\delta_t=0$, $P_t = P_{\\text{SOC}}$). Otherwise, the biologic strategy is continued.\n\nFinally, to compare the strategies on a common scale, the Net Monetary Benefit (NMB) is calculated. NMB converts the health gain (TotalQALY) into a monetary value using a willingness-to-pay threshold, $\\lambda$ (USD per QALY), and subtracts the total cost.\n$$\n\\text{NMB} = \\lambda \\cdot \\text{TotalQALY} - \\text{TotalCost}\n$$\nThe calculations are implemented using the `numpy` library for efficient vector and matrix operations. Each test case is processed by running the simulation with the specified parameters, and the resulting $[\\text{TotalCost}, \\text{TotalQALY}, \\text{NMB}]$ triplet is computed and rounded as required.",
            "answer": "```text\n[[103230.13,3.8647,283239.87],[20286.99,3.2929,309003.01],[68294.0,3.738,305506.0],[121966.39,4.0267,280703.61]]\n```"
        }
    ]
}